ArticleClinical immunology (Orlando, Fla.)2021

Brief report: Tempol, a novel antioxidant, inhibits both activated T cell and antigen presenting cell derived cytokines in-vitro from COVID-19 patients.

Kavita Mathi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.